1. Home
  2. IVA

as 07-23-2024 4:00pm EST

$
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

Founded: 2011 Country:
France
France
Employees: N/A City: N/A
Market Cap: 140.3M IPO Year: 2020
Target Price: $18.00 AVG Volume (30 days): 11.1K
Analyst Decision: Strong Buy Number of Analysts: 5
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -2.64 EPS Growth: N/A
52 Week Low/High: $2.47 - $4.75 Next Earning Date: 03-27-2024
Revenue: $25,736,667 Revenue Growth: 172.47%
Revenue Growth (this year): -87.46% Revenue Growth (next year): 360.85%

IVA Daily Stock ML Predictions

Share on Social Networks: